AdipoGen Life Sciences

anti-Sirtuin 2 (human), pAb

CHF 190.00

In stock

AG-25A-0083-C100100 µgCHF 190.00

Figure 1: Western blot analysis using anti-Sirtuin 2 (human), pAb (Prod. No. AG-25A-0083) at 1:4'000 dilution.
1: Human Sirtuin 2 (His-tagged).
2: Human FGF21 (His-tagged) (negative control).

Specifications / Handling

More Information
Product Details
Synonyms	SIRT2; NAD-dependent Deacetylase Sirtuin-2; SIR2-like protein 2; SIR2L2
Product Type	Polyclonal Antibody
Properties
Source/Host	Rabbit
Immunogen/Antigen	Recombinant human sirtuin 2.
Application	ELISA: (direct and indirect: 1:2’000-1:5’000) Western Blot: (1:2’000-1:5’000 using ECL; suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk; suggested incubation time is 1 hour at room temperature). Optimal conditions must be determined individually for each application. Note: Tested on recombinant proteins and/or target-protein transfected cell lines in ELISA, Western Blot and/or FACS.
Crossreactivity	Human
Specificity	Recognizes human sirtuin 2. Detects a band of ~45kDa by Western blot.
Purity Detail	Protein A-affinity purified.
Concentration	1mg/ml
Formulation	Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Isotype Negative Control	Rabbit IgG
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 6 months after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Sirtuin-2 is a NAD-dependent protein deacetylase, which deacetylates the 'Lys-40' of a-tubulin. It is involved in the control of mitotic exit in the cell cycle. Furthermore, a variety of age-associated diseases such as type 2 diabetes, obesity, osteoporosis, and Alzheimer’s disease are associated with sirtuins. Selective inhibition of Sirtuin-2 achieves neuroprotection and identifies Sirtuin-2 to be a potential therapeutic avenue in Huntington’s and Parkinson’s disease.

Call	+41 61 926 6040
Fax	+41 61 926 6049